Previous close | 4.9500 |
Open | 4.9500 |
Bid | 4.6200 x 100 |
Ask | 4.8400 x 100 |
Day's range | 4.6009 - 4.9500 |
52-week range | 4.0500 - 9.9400 |
Volume | |
Avg. volume | 51,467 |
Market cap | 84.993M |
Beta (5Y monthly) | -0.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 24 May 2022 |
1y target est | N/A |
Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2024Date: Wednesday, May 1
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase’s business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: ProPhase Labs Advances Cancer Treatment with Project ZenQ-AI - ProPhase Labs h
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was